Petros pharmaceuticals receives positive response from fda following recent demonstration of technology component in pursuit of otc status for stendra(r) (avanafil)

(please see important safety information below) new york, ny / accesswire / april 16, 2024 / petros pharmaceuticals, inc. ("petros," or the "company") (nasdaq:ptpi), a company focused on expanding consumer access to medication through over-the- counter (otc) drug development programs, announces it has received positive feedback from the u.s. food and drug administration (the "fda," or the "agency") following the fda's informal review of petros' technology component for self-selection as the company endeavors to achieve otc status for stendra. the agency acknowledged that the technology addressed some of its concerns regarding the pde5 inhibitor class in that context, particularly with regard to nitrate-using patients.
PTPI Ratings Summary
PTPI Quant Ranking